[go: up one dir, main page]
More Web Proxy on the site http://driver.im/
You seem to have javascript disabled. Please note that many of the page functionalities won't work as expected without javascript enabled.
 
 
Sign in to use this feature.

Years

Between: -

Subjects

remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline

Journals

Article Types

Countries / Regions

Search Results (143)

Search Parameters:
Keywords = time–kill curves

Order results
Result details
Results per page
Select all
Export citation of selected articles as:
17 pages, 5886 KiB  
Article
Interference of Celastrol with Cell Wall Synthesis and Biofilm Formation in Staphylococcus epidermidis
by Leandro de León Guerra, Nayely Padilla Montaño and Laila Moujir
Antibiotics 2025, 14(1), 26; https://doi.org/10.3390/antibiotics14010026 - 3 Jan 2025
Viewed by 551
Abstract
Background: The emergence of antibiotic-resistant bacteria, including Staphylococcus epidermidis, underscores the need for novel antimicrobial agents. Celastrol, a natural compound derived from the plants of the Celastraceae family, has demonstrated promising antibacterial and antibiofilm properties against various pathogens. Objectives: This study [...] Read more.
Background: The emergence of antibiotic-resistant bacteria, including Staphylococcus epidermidis, underscores the need for novel antimicrobial agents. Celastrol, a natural compound derived from the plants of the Celastraceae family, has demonstrated promising antibacterial and antibiofilm properties against various pathogens. Objectives: This study aims to evaluate the antibacterial effects, mechanism of action, and antibiofilm activity of celastrol against S. epidermidis, an emerging opportunistic pathogen. Methods: To investigate the mechanism of action of celastrol, its antibacterial activity was evaluated by determining the time–kill curves, assessing macromolecular synthesis, and analysing its impact on the stability and functionality of the bacterial cell membrane. Additionally, its effect on biofilm formation and disruption was examined. Results: Celastrol exhibited significant antibacterial activity with a minimal inhibitory concentration (MIC) of 0.31 μg/mL and minimal bactericidal concentration (MBC) of 15 μg/mL, which is superior to conventional antibiotics used as control. Time–kill assays revealed a concentration-dependent bactericidal effect, with a shift from bacteriostatic activity at lower concentrations to bactericidal and lytic effect at higher concentrations. Celastrol inhibited cell wall biosynthesis by blocking the incorporation of N-acetylglucosamine (NAG) into peptidoglycan. In contrast, the cytoplasmic membrane was only affected at higher concentrations of the compound or after prolonged exposure times. Additionally, celastrol was able to disrupt biofilm formation at concentrations of 0.9 μg/mL and to eradicate pre-formed biofilms at 7.5 μg/mL in S. epidermidis. Conclusions: Celastrol exhibits significant antibacterial and antibiofilm activities against S. epidermidis, with a primary action on cell wall synthesis. Its efficacy in disrupting the formation of biofilms and pre-formed biofilms suggests its potential as a therapeutic agent for infections caused by biofilm-forming S. epidermidis resistant to conventional treatments. Full article
(This article belongs to the Special Issue Antimicrobial and Antibiofilm Activity by Natural Compounds)
Show Figures

Graphical abstract

Graphical abstract
Full article ">Figure 1
<p>Chemical structure of celastrol.</p>
Full article ">Figure 2
<p>Killing curves of <span class="html-italic">S. epidermidis</span> in presence of celastrol or reference antibiotics. Untreated cell were used as a control. Compounds were added in lag-phase (<b>A</b>) and log-phase of growth after 4 h of preincubation (<b>B</b>). Error bars represent the standard deviation (SD) with <span class="html-italic">n</span> = 3.</p>
Full article ">Figure 3
<p>Effect of celastrol (15 μg/mL) on different inoculum sizes of <span class="html-italic">S. epidermidis</span> (ranging from 10<sup>3</sup> to 10<sup>8</sup> CFU/mL) at lag-phase of growth. Log<sub>10</sub> of CFU counts (<b>A</b>) and optical density of the cultures (<b>B</b>). Error bars represent the standard deviation (SD) with <span class="html-italic">n</span> = 3.</p>
Full article ">Figure 4
<p>Effect of celastrol at 15 μg/mL in the incorporation of radiolabeled precursors [6-<sup>3</sup>H] thymidine, [5-<sup>3</sup>H] uridine, [4,5-<sup>3</sup>H] leucine and N-Acetyl-D-[1-<sup>14</sup>C] glucosamine for the synthesis of DNA, RNA, protein and cell wall, respectively, in <span class="html-italic">S. epidermidis</span>. Data are expressed as percentage (%) of precursors incorporated compared to controls without drugs but with the maximum proportion of DMSO (100% of incorporation). Red line indicates 50% of inhibition. Error bars represent the standard deviation (SD) with <span class="html-italic">n</span> = 3. Different letters above bars mean significant differences between treated cultures within each given time point (<span class="html-italic">p</span> &lt; 0.05, one-way ANOVA; Tukey’s test).</p>
Full article ">Figure 5
<p>Effect of celastrol at 15 μg/mL in the uptake of radiolabeled precursors [6-<sup>3</sup>H] thymidine, [5-<sup>3</sup>H] uridine, [4,5-<sup>3</sup>H] leucine and N-Acetyl-D-[1-<sup>14</sup>C] glucosamine for the synthesis of DNA, RNA, protein and cell wall, respectively, in <span class="html-italic">S. epidermidis</span>. Data are expressed as percentage (%) of precursors uptaked compared to controls without drugs but with the maximum proportion of DMSO (100% of uptake). Red line indicates 50% of inhibition. Error bars represent the standard deviation (SD) with <span class="html-italic">n</span> = 3. Different letters above bars mean significant differences between treated cultures within each given time point (<span class="html-italic">p</span> &lt; 0.05, one-way ANOVA; Tukey’s test).</p>
Full article ">Figure 6
<p>Epifluorescence microscopy images of <span class="html-italic">S. epidermidis</span> stained with propidium iodide and Syto 9 after treatment with celastrol at 15 μg/mL for 60 min (<b>A</b>) and 120 min (<b>B</b>) or 30 μg/mL for 60 min (<b>C</b>) and 120 min (<b>D</b>).</p>
Full article ">Figure 7
<p>Effect of celastrol on the release of cytoplasmic components to the extracellular environment in <span class="html-italic">S. epidermidis.</span> Material absorbing at 260 nm (<b>A</b>) and 280 nm (<b>B</b>), and potassium release (<b>D</b>). Cell cultures treated with clofoctol served as positive control, while untreated cultures were used as negative control. Optical density at 435 nm (wavelength of maximal absorbance of celastrol) of cell suspension supernatant of <span class="html-italic">S. epidermidis</span> in saline buffer containing celastrol at 15 μg/mL (<b>C</b>). Error bars represent the standard deviation (SD) with <span class="html-italic">n</span> = 3.</p>
Full article ">Figure 8
<p>Transmission Electron Microscopy (TEM) of <span class="html-italic">S. epidermidis</span> cells treated with celastrol at 15 µg/mL for 1 h (<b>A</b>,<b>B</b>). Cell cultures without drugs but containing the maximum DMSO concentration were used as controls (<b>C</b>). Arrows indicate the presence of mesosome-like structures at the division septum site.</p>
Full article ">Figure 9
<p>Effect of celastrol to inhibit biofilm formation or eradicate pre-formed biofilm of <span class="html-italic">S. epidermidis</span>. The percentage of inhibition or eradication is shown relative to the untreated control (not displayed), which represents 0% inhibition or eradication. The error bars represent standard deviation from the mean value. Error bars represent the standard deviation (SD) with <span class="html-italic">n</span> = 3.</p>
Full article ">Figure 10
<p>Representative Scanning Electron Microscopy (SEM) images of <span class="html-italic">S. epidermidis</span> biofilm. (<b>A</b>,<b>B</b>) show untreated control cells with early biofilm formation after 24 h of culture. (<b>C</b>,<b>D</b>) illustrate the anti-adherence activity of celastrol (0.94 μg/mL) added at the beginning of the culture, resulting in dispersed cells and the inhibition of biofilm formation after 24 h. (<b>E</b>,<b>F</b>) depict the effect of celastrol (7.5 μg/mL) after 24 h of treatment on a pre-formed biofilm, showing disruption and eradication of typical cell aggregates observed in untreated cultures.</p>
Full article ">
16 pages, 2448 KiB  
Article
In Vitro Activity of Ampicillin Plus Ceftriaxone Against Non-faecalis and Non-faecium Enterococcal Isolates With/Without VanC Phenotype: Clinical Implications for Infective Endocarditis
by Javier García-González, María A. Cañas, Guillermo Cuervo, Marta Hernández-Meneses, Miguel A. Verdejo, Marta Bodro, Javier Díez de los Ríos, Oriol Gasch, Alba Ribera, Carles Falces, Andrés Perissinotti, Bárbara Vidal, Eduard Quintana, Asunción Moreno, Maria Piquet, Ignasi Roca, Mariana Fernández-Pittol, Sol M. San José-Villar, Cristina García-de-la-Mària, José M. Miró and the Hospital Clínic Endocarditis Study Groupadd Show full author list remove Hide full author list
Microorganisms 2024, 12(12), 2511; https://doi.org/10.3390/microorganisms12122511 - 5 Dec 2024
Viewed by 1036
Abstract
(1) Background: Alternative antibiotics are needed to treat infective endocarditis (IE) caused by non-faecalis/non-faecium enterococci; we aimed to assess the in vitro activity of ampicillin plus ceftriaxone (AMP + CTR) against these enterococci and to describe its clinical efficacy in [...] Read more.
(1) Background: Alternative antibiotics are needed to treat infective endocarditis (IE) caused by non-faecalis/non-faecium enterococci; we aimed to assess the in vitro activity of ampicillin plus ceftriaxone (AMP + CTR) against these enterococci and to describe its clinical efficacy in IE cases. (2) Methods: Time–kill curves with standard (ISI) and high (IHI) inocula were performed to test VanC isolates [3 E. casseliflavus (ECAS) and 1 E. gallinarum (EGALL)] and non-VanC isolates [1 E. durans (EDUR), 1 E. hirae (EHIR) and 1 E. raffinosus (ERAF)]. The narrative literature review of IE cases treated with AMP + CTR was analyzed alongside three study cases. Clinical outcomes were relapse and death. (3) Results: Ampicillin plus gentamicin (AMP + GEN) showed synergistic and bactericidal activity against most isolates. AMP + CTR was synergistic at ISI for EGALL, EDUR, and EHIR and bactericidal against EHIR. At IHI, indifferent activity was observed for all isolates. In IE cases treated with AMP + CTR, it was only effective for EDUR and EHIR. Clinical information for EGALL IE is lacking. For IE caused by ECAS and ERAF, AMP + CTR seems suboptimal or ineffective, respectively. (4) AMP + CTR cannot be recommended for treating IE due to ECAS/ERAF. In contrast, this combination was effective in IE caused by EDUR/EHIR and could be recommended. Full article
(This article belongs to the Special Issue The Infective Endocarditis)
Show Figures

Figure 1

Figure 1
<p>Ampicillin (AMP) plus gentamicin (GEN) time–kill curves for the study isolates: ECAS-1219, ECAS-1247, ECAS-1461, EDUR-440, EHIR-1400, ERAF-1465, and EGALL-PT. The isolates were classified in the VanC phenotype (<b>A</b>,<b>B</b>): (<b>A</b>) Initial standard inoculum (ISI) and (<b>B</b>) initial higher inoculum (IHI) or no VanC phenotype (<b>C</b>,<b>D</b>): (<b>C</b>) ISI and (<b>D</b>) IHI. The black circle indicates growth control; the inverted black triangle indicates GEN monotherapy; the black triangle indicates AMP monotherapy; and the red square indicates combined therapy. The blue line indicates bactericidal activity. At ISI, the isolates were incubated with AMP + GEN at concentrations of 1×MIC for both antibiotics. At IHI, the isolates were incubated with AMP + GEN at concentrations of 20 mg/L for AMP and 8 mg/L for GEN. Values are the mean standard deviations from two independent experiments.</p>
Full article ">Figure 1 Cont.
<p>Ampicillin (AMP) plus gentamicin (GEN) time–kill curves for the study isolates: ECAS-1219, ECAS-1247, ECAS-1461, EDUR-440, EHIR-1400, ERAF-1465, and EGALL-PT. The isolates were classified in the VanC phenotype (<b>A</b>,<b>B</b>): (<b>A</b>) Initial standard inoculum (ISI) and (<b>B</b>) initial higher inoculum (IHI) or no VanC phenotype (<b>C</b>,<b>D</b>): (<b>C</b>) ISI and (<b>D</b>) IHI. The black circle indicates growth control; the inverted black triangle indicates GEN monotherapy; the black triangle indicates AMP monotherapy; and the red square indicates combined therapy. The blue line indicates bactericidal activity. At ISI, the isolates were incubated with AMP + GEN at concentrations of 1×MIC for both antibiotics. At IHI, the isolates were incubated with AMP + GEN at concentrations of 20 mg/L for AMP and 8 mg/L for GEN. Values are the mean standard deviations from two independent experiments.</p>
Full article ">Figure 2
<p>Ampicillin (AMP) plus ceftriaxone (CTR) time–kill curves for the study isolates: ECAS-1219, ECAS-1247, ECAS-1461, EDUR-440, EHIR-1400, ERAF-1465, and EGALL-PT. The isolates were classified in the VanC phenotype (<b>A</b>,<b>B</b>): (<b>A</b>) Initial standard inoculum (ISI) and (<b>B</b>) initial higher inoculum (IHI) or no VanC phenotype (<b>C</b>,<b>D</b>): (<b>C</b>) ISI and (<b>D</b>) IHI. The black circle indicates growth control; the inverted black triangle indicates CTR monotherapy; the black triangle indicates AMP monotherapy; and the red square indicates combined therapy. The blue line indicates bactericidal activity. At ISI, the isolates were incubated with AMP + CTR at concentrations of 1×MIC for both antibiotics. At IHI, the isolates were incubated with AMP + CTR at concentrations of 20 mg/L for AMP and 64 mg/L for CTR. Values are the mean standard deviations from two independent experiments.</p>
Full article ">Figure 2 Cont.
<p>Ampicillin (AMP) plus ceftriaxone (CTR) time–kill curves for the study isolates: ECAS-1219, ECAS-1247, ECAS-1461, EDUR-440, EHIR-1400, ERAF-1465, and EGALL-PT. The isolates were classified in the VanC phenotype (<b>A</b>,<b>B</b>): (<b>A</b>) Initial standard inoculum (ISI) and (<b>B</b>) initial higher inoculum (IHI) or no VanC phenotype (<b>C</b>,<b>D</b>): (<b>C</b>) ISI and (<b>D</b>) IHI. The black circle indicates growth control; the inverted black triangle indicates CTR monotherapy; the black triangle indicates AMP monotherapy; and the red square indicates combined therapy. The blue line indicates bactericidal activity. At ISI, the isolates were incubated with AMP + CTR at concentrations of 1×MIC for both antibiotics. At IHI, the isolates were incubated with AMP + CTR at concentrations of 20 mg/L for AMP and 64 mg/L for CTR. Values are the mean standard deviations from two independent experiments.</p>
Full article ">Figure 3
<p>Results from the PFGE and FTIR analysis.</p>
Full article ">Figure 4
<p>Flowchart summarizing the selection of manuscripts for this narrative review. This work is licensed under CC BY 4.0. To view a copy of this license, visit: <a href="https://creativecommons.org/licenses/by/4.0/" target="_blank">https://creativecommons.org/licenses/by/4.0/</a> (accessed on 31 October 2024) Source: [<a href="#B28-microorganisms-12-02511" class="html-bibr">28</a>].</p>
Full article ">
16 pages, 6809 KiB  
Article
A New Approach to Evaluate the Bactericidal Activity of Different Antiseptic Ophthalmic Preparations Used as Surgical Prophylaxis
by Sara Caldrer, Niccolò Deotto, Marco G. Prato, Natasha Gianesini, Milena Bernardi, Pierantonio Orza, Federico G. Gobbi, Grazia Pertile and Chiara Piubelli
Antibiotics 2024, 13(11), 1051; https://doi.org/10.3390/antibiotics13111051 - 6 Nov 2024
Viewed by 922
Abstract
Background: A survey conducted by the European Observatory on Cataract Surgery showed high heterogeneity in the use of antiseptics both preoperatively and in the operating room, highlighting the absence of a global consensus regarding ocular infection prophylaxis in cataract surgery. Methods: [...] Read more.
Background: A survey conducted by the European Observatory on Cataract Surgery showed high heterogeneity in the use of antiseptics both preoperatively and in the operating room, highlighting the absence of a global consensus regarding ocular infection prophylaxis in cataract surgery. Methods: The antibacterial activity of seven antiseptic ophthalmic formulations (AOFs) registered as medical devices and the two most common disinfectants were evaluated in vitro against five bacterial species. The viability of bacterial strains after exposure to the antiseptic was evaluated with different techniques: the in vitro Minimum Inhibitory Concentration and the subsequent Minimum Bactericidal Concentration, performed on liquid and solid culture medium. Furthermore, a real-time assessment of bacterial viability was conducted using double staining for live/dead bacterial cells by fluorimetric assay. This evaluation was performed on both the time-killing curve and the tear dilution effect test. Results: We observed a high variability across the different AOFs in terms of inhibitory/bactericidal concentration and timing on Gram-positive and Gram-negative bacterial classes. The results indicated that among the tested AOFs, Visuprime, Iodim, and Oftasteril were the most rapid and effective for ocular surface disinfection against the tested bacterial species. Conclusions: The obtained results can support the clinician’s choice of the most suitable AOF for the prevention and treatment of ophthalmic infections associated with surgery. Full article
Show Figures

Figure 1

Figure 1
<p>Study design representing the different techniques employed, classified according to the time of incubation.</p>
Full article ">Figure 2
<p>Heat map representing the MIC (orange square) and MBC (blue scale square) values for each bacterial species ((<b>A</b>,<b>B</b>) for Gram-positive; (<b>C</b>–<b>E</b>) for Gram-negative), after 24 h (for MIC) and 48 h (for MBC) of AOF exposure. Bacteria growth was expressed in CFU/mL. Assays were executed in biological triplicate and reported as mean.</p>
Full article ">Figure 3
<p>Heat map representing the relative frequency of live bacteria (blue scale square) values for each bacterial species ((<b>A</b>,<b>B</b>) for Gram-positive; (<b>C</b>–<b>E</b>) for Gram-negative), after 24 h of AOF exposure. Bacteria viability was expressed as % of green emission/total bacteria events. The MBC value forecasted by the FCM was represented by the orange squares.</p>
Full article ">Figure 4
<p>The TKC representing bacteria viability after 1–8 min of AOF exposure for each bacteria strain ((<b>A</b>,<b>B</b>) for Gram-positive; (<b>C</b>–<b>E</b>) for Gram-negative). Bacteria viability was expressed as CFU after 24 h of plate culture. NT control represented the value obtained by seeding 150 CFU of bacteria species. The efficacy control was obtained using CLX 0.05% (orange dashed line). The lines of Iodim, Oftasteril, and Visuprime are so close together that they are indistinguishable from each other, so we have nudged the lines above and below the zero line to better distinguish the trace of the three compounds.</p>
Full article ">Figure 5
<p>Time-killing curve representing bacteria viability after different time points of AOF exposure. Bacteria viability, of each bacteria strain ((<b>A</b>,<b>B</b>) for Gram-positive; (<b>C</b>–<b>E</b>) for Gram-negative), was measured in real time by FSP method and was expressed on AFU (N0/N). Orange dashed line represents the CLX 0.05% values that were used as efficacy control. Grey area represents the CLX 0.05% + 20% to define the efficacy of AOFs.</p>
Full article ">Figure 6
<p>TFMC represents bacteria viability after different time points of AOF exposure. Bacteria viability, of each bacteria strain ((<b>A</b>,<b>B</b>) for Gram-positive; (<b>C</b>–<b>E</b>) for Gram-negative), was measured in real time by FMR method and was expressed as AFU (N0/N). In this kinetic test, 150 CFU of each bacteria species were exposed to the different AOFs at the minimal dilution (75%). Subsequently, every minute, we mimicked the physiological “tears dilution” by a 15% reduction of both AOFs and bacterial concentration on the ocular surface. As NT control, the fluorescence emitted by live bacteria (150 CFU) was measured being diluted by 15% every minute. In instances where AOF lines were in such close proximity that they were indistinguishable from one another, we relocated the lines below the zero line with the objective of facilitating the differentiation of the traces of the various compounds.</p>
Full article ">
20 pages, 3017 KiB  
Article
A Novel PCR-Free Ultrasensitive GQD-Based Label-Free Electrochemical DNA Sensor for Sensitive and Rapid Detection of Francisella tularensis 
by Sumeyra Savas and Melike Sarıçam
Micromachines 2024, 15(11), 1308; https://doi.org/10.3390/mi15111308 - 28 Oct 2024
Viewed by 1057
Abstract
Biological warfare agents are infectious microorganisms or toxins capable of harming or killing humans. Francisella tularensis is a potential bioterrorism agent that is highly infectious, even at very low doses. Biosensors for biological warfare agents are simple yet reliable point-of-care analytical tools. Developing [...] Read more.
Biological warfare agents are infectious microorganisms or toxins capable of harming or killing humans. Francisella tularensis is a potential bioterrorism agent that is highly infectious, even at very low doses. Biosensors for biological warfare agents are simple yet reliable point-of-care analytical tools. Developing highly sensitive, reliable, and cost-effective label-free DNA biosensors poses significant challenges, particularly when utilizing traditional techniques such as fluorescence, electrochemical methods, and others. These challenges arise primarily due to the need for labeling, enzymes, or complex modifications, which can complicate the design and implementation of biosensors. In this study, we fabricated Graphene Quantum dot (GQD)-functionalized biosensors for highly sensitive label-free DNA detection. GQDs were immobilized on the surface of screen-printed gold electrodes via mercaptoacetic acid with a thiol group. The single-stranded DNA (ssDNA) probe was also immobilized on GQDs through strong π−π interactions. The ssDNA probe can hybridize with the ssDNA target and form double-stranded DNA, leading to a decrease in the effect of GQD but a positive shift associated with the increase in DNA concentration. The specificity of the developed system was observed with different microorganism target DNAs and up to three-base mismatches in the target DNA, effectively distinguishing the target DNA. The response time for the target DNA molecule is approximately 1010 s (17 min). Experimental steps were monitored using UV/Vis spectroscopy, Atomic Force Microscopy (AFM), and electrochemical techniques to confirm the successful fabrication of the biosensor. The detection limit can reach 0.1 nM, which is two–five orders of magnitude lower than previously reported methods. The biosensor also exhibits a good linear range from 105 to 0.01 nM and has good specificity. The biosensor’s detection limit (LOD) was evaluated as 0.1 nM from the standard calibration curve, with a correlation coefficient of R2 = 0.9712, showing a good linear range and specificity. Here, we demonstrate a cost-effective, GQD-based SPGE/F. tularensis DNA test suitable for portable electrochemical devices. This application provides good perspectives for point-of-care portable electrochemical devices that integrate sample processing and detection into a single cartridge without requiring a PCR before detection. Based on these results, it can be concluded that this is the first enzyme-free electrochemical DNA biosensor developed for the rapid and sensitive detection of F. tularensis, leveraging the nanoenzyme and catalytic properties of GQDs. Full article
(This article belongs to the Special Issue Biosensors for Pathogen Detection 2024)
Show Figures

Figure 1

Figure 1
<p>Principle of the GQD-based DNA sensor for <span class="html-italic">F. tularensis</span> detection.</p>
Full article ">Figure 2
<p>(<b>a</b>) Cyclic voltammetry measurement to determine the most ideal amperometric measurement. (<b>b</b>) Real time measurement curves obtained with four different GQDs concentrations. (<b>c</b>) Optical properties of GQDs at decreasing concentrations.</p>
Full article ">Figure 3
<p>Comparative UV/Vis spectra of GQDs, GQDs-N, GQDs-Capture DNA, GQDs-BSA and GQDs-Target DNA.</p>
Full article ">Figure 4
<p>Optimization of the ideal hybridization time between capture DNA (ssDNA) and 10<sup>5</sup> nM target DNA (gDNA) on the sensor surface.</p>
Full article ">Figure 5
<p>(<b>a</b>) The amperometric measurement curves obtained for eight concentrations of <span class="html-italic">F. tularensis</span> DNA (dsDNA) concentration using 5000 ppm GQDs, 5000 ppm GQDs, and GQDs-ssDNA attachment. (<b>b</b>) The linear calibration curve of DNA assays (10<sup>5</sup> nM–0.1 nM) with a correlation coefficient of 0.9712. (<b>c</b>) Sensogram of eight concentrations of <span class="html-italic">F. tularensis</span> DNA (dsDNA). (<b>d</b>) The amperometric measurement curves obtained only between 10 nM–0.01 nM.</p>
Full article ">Figure 5 Cont.
<p>(<b>a</b>) The amperometric measurement curves obtained for eight concentrations of <span class="html-italic">F. tularensis</span> DNA (dsDNA) concentration using 5000 ppm GQDs, 5000 ppm GQDs, and GQDs-ssDNA attachment. (<b>b</b>) The linear calibration curve of DNA assays (10<sup>5</sup> nM–0.1 nM) with a correlation coefficient of 0.9712. (<b>c</b>) Sensogram of eight concentrations of <span class="html-italic">F. tularensis</span> DNA (dsDNA). (<b>d</b>) The amperometric measurement curves obtained only between 10 nM–0.01 nM.</p>
Full article ">Figure 6
<p>AFM 3D topography images of (<b>a</b>) GQD-laminated surface, (<b>b</b>) Capture DNA immobilized and (<b>c</b>) After hybridizationTarget DNA binding.</p>
Full article ">Figure 7
<p>Current responses for the detection of non-complementary DNA targets (<span class="html-italic">Salmonella</span> spp. target <span class="html-italic">Y. pestis</span> target), three-base mismatched DNA targets, one-base mismatched DNA targets, and complementary DNA targets.</p>
Full article ">Figure 8
<p>Gel electrophoresis experiments to verify the applicability of the DNA chains designed in the article (the forward primer: GCT GTA TCA TCA TTT AAT AAA CTG CTG and reverse primer: TTG GGA AGC TTG TAT CAT GGC ACT pair was used and a tul4 gene of 428 bp size was detected).</p>
Full article ">Figure 9
<p>Comparison of the similarity ratios for the same concentrations measured in three different measurements.</p>
Full article ">
19 pages, 7028 KiB  
Article
Enhancing Gentamicin Antibacterial Activity by Co-Encapsulation with Thymoquinone in Liposomal Formulation
by Raghad R. Alzahrani, Manal M. Alkhulaifi, Majed Al Jeraisy, Abdulkareem M. Albekairy, Rizwan Ali, Bahauddeen M. Alrfaei, Salleh N. Ehaideb, Ahmed I. Al-Asmari, Sultan Al Qahtani, Abdulaziz Halwani, Alaa Eldeen B. Yassin and Majed A. Halwani
Pharmaceutics 2024, 16(10), 1330; https://doi.org/10.3390/pharmaceutics16101330 - 15 Oct 2024
Viewed by 1716
Abstract
Background and Purpose. Gentamicin (GEN) is a broad-spectrum antibiotic that cannot be prescribed freely because of its toxicity. Thymoquinone (THQ), a phytochemical, has antibacterial, antioxidant, and toxicity-reducing properties. However, its hydrophobicity and light sensitivity make it challenging to utilize. This incited the idea [...] Read more.
Background and Purpose. Gentamicin (GEN) is a broad-spectrum antibiotic that cannot be prescribed freely because of its toxicity. Thymoquinone (THQ), a phytochemical, has antibacterial, antioxidant, and toxicity-reducing properties. However, its hydrophobicity and light sensitivity make it challenging to utilize. This incited the idea of co-encapsulating GEN and THQ in liposomes (Lipo-GEN-THQ). Method. Lipo-GEN-THQ were characterized using the zeta-potential, dynamic light scattering, Fourier transform infrared spectroscopy, and transmission electron microscope (TEM). The liposomes’ stability was evaluated under different storage and biological conditions. Lipo-GEN-THQ’s efficacy was investigated by the minimum inhibitory/bactericidal concentrations (MICs-MBCs), time–kill curves, and antibiofilm and antiadhesion assays. Bacterial interactions with the empty and GEN-THQ-loaded liposomes were evaluated using TEM. Results. The Lipo-GEN-THQ were spherical, monodispersed, and negatively charged. The Lipo-GEN-THQ were relatively stable and released GEN sustainably over 24 h. The liposomes exhibited significantly higher antibacterial activity than free GEN, as evidenced by the four-fold lower MIC and biofilm eradication in resistant E. coli strain (EC-219). TEM images display how the empty liposomes fused closely to the tested bacteria and how the loaded liposomes caused ultrastructure damage and intracellular component release. An antiadhesion assay showed that the Lipo-GEN-THQ and free GEN (0.125 mg/L) similarly inhibited Escherichia coli (EC-157) adhesion to the A549 cells (68% vs. 64%). Conclusions. The Lipo-THQ-GEN enhanced GEN by combining it with THQ within the liposomes, reducing the effective dose. The reduction in the GEN dose after adding THQ may indirectly reduce the toxicity and aid in developing an enhanced and safer form of GEN. Full article
Show Figures

Figure 1

Figure 1
<p>TEM imaging of the spherical Lipo-GEN-THQ formulation at a magnification of 120 K. The inset image (white frame) displays a group of spherical liposomes at a magnification of 80 K; scale bars, 200 nm. Note: the sharpness was enhanced.</p>
Full article ">Figure 2
<p>Lipo-GEN-THQ size and PDI stabilities in dH<sub>2</sub>O at room temperature in hours.</p>
Full article ">Figure 3
<p>FTIR spectra: (<b>A</b>) thymoquinone (THQ); (<b>B</b>) gentamicin (GEN); (<b>C</b>) empty liposomes; (<b>D</b>) liposomal gentamicin–thymoquinone (Lipo-GEN-THQ) formula.</p>
Full article ">Figure 4
<p>Drug-release assay of Lipo-GEN-THQ under different conditions. The Lipo-GEN-THQ formula was relatively stable in PBS at 4 °C (circle) and 37 °C (square), sputum (upright triangle), plasma (inverted triangle), and BALF (rhombus) and released GEN gradually. The results were averaged and normalized to the mean of the retained GEN at time 0.</p>
Full article ">Figure 5
<p>TEM imaging of empty liposomes closely aggregating and fusing to (<b>A</b>) <span class="html-italic">E. coli</span> ATCC 25922 and (<b>B</b>) a susceptible clinical isolate of <span class="html-italic">E. coli</span> (EC-157). Arrows are directed toward the liposomes; scale bars, 200 nm. Note: the sharpness was enhanced.</p>
Full article ">Figure 6
<p>TEM images of a susceptible clinical strain of <span class="html-italic">E. coil</span> (EC-157) after one hour of exposure to the MICs of Lipo-GEN-THQ formula and free gentamicin: (<b>A</b>,<b>B</b>) untreated cells showing intact outer membranes and evenly distributed periplasmic spaces; (<b>C</b>–<b>F</b>) treated cells, with bacterial cell cross-sections (insets) showing inner changes. Black arrows point to damage to the outer membrane and the extended periplasmic space, and white arrows point to intracellular component release; scale bars, 500 nm. Note: the sharpness was enhanced.</p>
Full article ">Figure 7
<p>Time–kill curves of different concentrations of Lipo-GEN-THQ and free GEN against (<b>A</b>) <span class="html-italic">E. coli</span> ATCC 25922 and (<b>B</b>) a clinical strain of <span class="html-italic">E. coli</span> (EC-219). Untreated cells (control, circle), Lipo-GEN-THQ (MIC, square; Sub-MIC, upright triangle), and free GEN (MIC, upside tringle; Sub-MIC, rhombus).</p>
Full article ">Figure 8
<p>Biofilm inhibition assay of Lipo-GEN-THQ’s and free GEN’s Sub-MICs against (<b>A</b>) <span class="html-italic">E. coli</span> ATCC 25922 (** <span class="html-italic">p</span> ≤ 0.001) and (<b>B</b>) <span class="html-italic">E.coli</span> EC-219 (resistant clinical strain) (** <span class="html-italic">p</span> ≤ 0.002). Biofilm eradication assays of Lipo-GEN-THQ and free GEN against (<b>C</b>) <span class="html-italic">E. coli</span> ATCC 25922 (*** <span class="html-italic">p</span> ≤ 0.0005) and (<b>D</b>) <span class="html-italic">E.coli</span> EC-219 (resistant clinical strain) (** <span class="html-italic">p</span> ≤ 0.01 and <span class="html-italic">ns</span> = nonsignificant). The analysis was conducted using a one-way ANOVA test followed by Tukey’s multiple comparison test. The results are the mean of at least quadruplets; bars show the standard deviation.</p>
Full article ">Figure 9
<p>Antiadhesion assays of serial concentrations of the Lipo-GEN-THQ formula and free GEN. Percentages represent the inhibition percentages. The tested concentrations ranged from 0.125 to 0.03 mg/L against the susceptible strain EC-157. **** <span class="html-italic">p</span> &lt; 0.0001, * <span class="html-italic">p</span> = 0.05, and <span class="html-italic">ns</span> = nonsignificant, One-way ANOVA, followed by Dunnett multiple comparison tests.</p>
Full article ">
22 pages, 15770 KiB  
Article
Enhancement of Fluoride’s Antibacterial and Antibiofilm Effects against Oral Staphylococcus aureus by the Urea Derivative BPU
by Jia Liu, Qingqing Weng, Dongxin Da, Shuran Yao, Ying Zhang and Yang Wu
Antibiotics 2024, 13(10), 930; https://doi.org/10.3390/antibiotics13100930 - 30 Sep 2024
Cited by 1 | Viewed by 1589
Abstract
Background: The oral cavity is an important but often overlooked reservoir for Staphylococcus aureus. The effective control and prevention of S. aureus colonization and infection in the oral and maxillofacial regions are crucial for public health. Fluoride is widely used in dental [...] Read more.
Background: The oral cavity is an important but often overlooked reservoir for Staphylococcus aureus. The effective control and prevention of S. aureus colonization and infection in the oral and maxillofacial regions are crucial for public health. Fluoride is widely used in dental care for its remineralization and antibacterial properties. However, its effectiveness against S. aureus has not been thoroughly investigated. Objectives: This study aimed to evaluate the potential of combining sodium fluoride (NaF) with compounds to enhance its antibacterial and antibiofilm effects against S. aureus. Method: We found that a urea derivative significantly enhances the efficacy of fluoride by promoting the retention of fluoride ions within the cells. The synergistic antibacterial and antibiofilm effects of BPU with NaF were confirmed through various assays, including checkerboard assays, time-kill assays, and growth curve analysis. These findings were further supported by additional methods, including transmission electron microscopy (TEM), in silico simulations, and gene overexpression studies. Results: These findings suggest that targeting fluoride ion membrane exporters could enhance antibacterial efficacy. When combined with fluoride, 1,3-Bis [3,5-bis(trifluoromethyl)phenyl]urea (BPU) showed increased effectiveness in inhibiting S. aureus growth and reducing established biofilms. Conclusions: This novel combination represents a promising therapeutic strategy for treating biofilm-associated S. aureus infections, offering a new strategy in oral healthcare. To fully evaluate the clinical potential of this synergistic therapy, further in vivo studies are essential. Full article
Show Figures

Figure 1

Figure 1
<p>Synergistic antibacterial activity of BPU and fluoride against <span class="html-italic">S. aureus.</span> (<b>A</b>) Chemical structure of the BPU molecule. (<b>B</b>) The checkerboard assay showing the interaction between BPU and fluoride. (<b>C</b>) Growth curves of <span class="html-italic">S. aureus</span> in different TSB media were monitored by measuring the optical density at 600 nm (OD600) every 1 h. (<b>D</b>) Intracellular fluoride levels were measured using ion chromatography (n = 3, *: <span class="html-italic">p</span> &lt; 0.05, ***: <span class="html-italic">p</span> &lt; 0.001, ****: <span class="html-italic">p</span> &lt; 0.0001).</p>
Full article ">Figure 2
<p>(<b>A</b>) Time-kill assay of <span class="html-italic">S. aureus</span> under different treatments, presented as survival rate. Data are expressed as mean ± SEM, n = 3. (<b>B</b>–<b>M</b>) TEM images of <span class="html-italic">S. aureus</span> under different treatments. (<b>B</b>–<b>D</b>) Control group: intact cell walls and well-defined structures. (<b>E</b>–<b>G</b>) BPU (156.25 mM) treatment: slight deformation, irregular cell walls, and minor cytoplasmic changes. (<b>H</b>–<b>J</b>) NaF (16 mM) treatment: pronounced disruption, including vacuoles in the cytoplasm. (<b>K</b>–<b>M</b>) Combined BPU and NaF treatment: severe alterations, including extensive cell wall disruption, vacuole formation, and cytoplasmic leakage. Images are presented at different magnifications: (<b>B</b>,<b>E</b>,<b>H</b>,<b>K</b>) 4000× (×4.0 k) with a scale bar of 2 µm; (<b>C</b>,<b>F</b>,<b>I</b>,<b>L</b>) 24,000× (×24.0 k) with a scale bar of 500 nm; (<b>D</b>,<b>G</b>,<b>J</b>,<b>M</b>) 60,000× (×60.0 k) with a scale bar of 200 nm.</p>
Full article ">Figure 3
<p>Effects of BPU on different <span class="html-italic">S. aureus</span> strains. (<b>A</b>) MIC values of BPU for various <span class="html-italic">S. aureus</span> strains, including USA300, USA500, ATCC 29213, Newman, and a clinical strain (n = 3). (<b>B</b>–<b>F</b>) Growth curves of <span class="html-italic">S. aureus</span> strains in response to varying concentrations of BPU.</p>
Full article ">Figure 4
<p>Eradication of mature biofilms by combined NaF and BPU. (<b>A</b>) Crystal violet-stained images of 24 h biofilms treated with 0.01% DMSO, NaF, BPU, or their combination. (<b>B</b>) Semi-quantitative biofilm measured by OD<sub>570</sub> from five replicates (****: <span class="html-italic">p</span> &lt; 0.0001, ns: not significant). (<b>C</b>) Confocal microscopy images of treated biofilms, with green (biofilm density) and red (cell damage) fluorescence quantified using ImageJ 1.54k.</p>
Full article ">Figure 5
<p>Analysis of interactions between BPU and the fluoride ion channel. (<b>A</b>) Three-dimensional structure of the dimerized protein. (<b>B</b>) Predicted binding site within the concave cavity of the dimer. (<b>C</b>) Hydrophobic interactions and hydrogen bonds between BPU and key amino acids, stabilizing the binding. (<b>D</b>) Detailed 2D interaction.</p>
Full article ">Figure 6
<p>Impact of <span class="html-italic">crcB1</span>&amp;<span class="html-italic">2</span> Overexpression on <span class="html-italic">S. aureus</span> USA300 Growth with NaF and BPU Treatments. (<b>A</b>–<b>C</b>) Growth of wild-type USA300 (<b>A</b>), USA300-pCM29 (<b>B</b>), and USA300-pCM29-<span class="html-italic">crcB1</span>&amp;<span class="html-italic">2</span> (<b>C</b>) with varying NaF concentrations. <span class="html-italic">crcB1</span>&amp;<span class="html-italic">2</span> overexpression led to higher OD<sub>600</sub> values at 16 mM and 64 mM NaF. (<b>D</b>–<b>F</b>) BPU treatment showed dose-dependent inhibition across all strains, with no significant differences observed. (<b>G</b>–<b>I</b>) Combined treatment with 8 mM NaF and BPU: the strain overexpressing <span class="html-italic">crcB1</span>&amp;<span class="html-italic">2</span> (<b>I</b>) exhibited higher OD<sub>600</sub> values at 0.15625 µM, 0.3125 µM, and 0.625 µM of BPU, indicating a requirement for higher BPU concentrations to achieve similar growth inhibition.</p>
Full article ">Figure 7
<p>Cytotoxic Assay of BPU. The biocompatibility of BPU was assessed using HGFs. (<b>A</b>) CCK-8 assay results. (<b>B</b>) Each row corresponds to a treatment group (Control, 0.01% DMSO, and 10 µM BPU), while the two columns display the microscopic morphology of HGFs at 0 and 12 h, respectively. The images from the Control group depict the morphology of untreated cells. In each set of images, the left images are at 40× magnification with a scale bar of 100 µm, providing an overview of the cell population, while the right images are at 100× magnification with a scale bar of 50 µm, offering a closer examination of cellular morphology details.</p>
Full article ">Figure 8
<p>Antibacterial Mechanism of BPU and Fluoride Against <span class="html-italic">S. aureus.</span></p>
Full article ">
11 pages, 1784 KiB  
Article
Post-Antibiotic and Post-Antibiotic Sub-Minimum Inhibitory Concentration Effects of Carvacrol against Salmonella Typhimurium
by Eva Boyer, Ángela Galán-Relaño, Antonio Romero-Salmoral, Paula Barraza, Lidia Gómez-Gascón, Carmen Tarradas, Inmaculada Luque, Fabiana Carolina de Aguiar and Belén Huerta Lorenzo
Animals 2024, 14(18), 2631; https://doi.org/10.3390/ani14182631 - 11 Sep 2024
Viewed by 888
Abstract
Carvacrol is a compound present in essential oils with proven antimicrobial activity against numerous pathogens. We firstly determine the post-antibiotic effect (PAE) of carvacrol (1×, 2×, 4× MIC) and post-antibiotic sub-minimum inhibitory concentration (MIC) effect (1× + 0.25× MIC and 2× + 0.25× [...] Read more.
Carvacrol is a compound present in essential oils with proven antimicrobial activity against numerous pathogens. We firstly determine the post-antibiotic effect (PAE) of carvacrol (1×, 2×, 4× MIC) and post-antibiotic sub-minimum inhibitory concentration (MIC) effect (1× + 0.25× MIC and 2× + 0.25× MIC) for two concentrations of Salmonella Typhimurium ATCC14028 (106 and 108 CFU/mL). Prior to testing, the minimum concentration and exposure time to achieve the bacterial inhibition (MIC 0.6 mg/mL and 10 min) were determined by broth microdilution and time–kill curve methods, respectively. At the MIC, carvacrol did not generate any PAE. At twice the MIC, the PAE was 2 h with the standard inoculum (106 CFU/mL) and 1 h with the high-density inoculum (108 CFU/mL). At 4× MIC concentrations, the PAE was higher in both cases > 43.5 h. Continuous exposure of post-antibiotic phase bacteria (1× and 2× MIC) to carvacrol at 0.25× MIC (0.15 mg/mL) resulted in an increase in PAE (PA-SME) above 43.5 h with both inocula. These results suggest that the PA-SME of carvacrol for S. Typhimurium can be significantly prolonged by increasing the sub-MICs, which would allow dose spacing, reduce adverse effects and improve its efficacy in the treatment of infected animals and as a disinfectant in agri-food facilities. Full article
(This article belongs to the Special Issue Salmonella and Salmonellosis: Implications in Public Health)
Show Figures

Figure 1

Figure 1
<p>(<b>A</b>) Lethality curve of different concentrations of carvacrol against a 10<sup>6</sup> CFU/mL inoculum of <span class="html-italic">Salmonella</span> Typhimurium ATCC 14028. (<b>B</b>) Enlargement of the results obtained in the first hour of the test. The horizontal dotted lines represent the theoretical cut-off points to evaluate the efficacy of the antimicrobial (reduction with respect to the initial inoculum): bacteriostatic effect (reduction ≥ 2 log<sub>10</sub>), bactericidal (reduction ≥ 3 log<sub>10</sub>) and virtual eradication of bacteria (reduction ≥ 4 log<sub>10</sub>). MIC 600 μg/mL.</p>
Full article ">Figure 2
<p>(<b>A</b>) Lethality curve of different concentrations of carvacrol against a 10<sup>8</sup> CFU/mL inoculum of <span class="html-italic">Salmonella</span> Typhimurium ATCC 14028. (<b>B</b>) Enlargement of the results obtained in the first hour of the test. The horizontal dotted lines represent the theoretical cut-off points to evaluate the efficacy of the antimicrobial (reduction with respect to the initial inoculum): bacteriostatic effect (reduction ≥ 2 log<sub>10</sub>), bactericidal (reduction ≥ 3 log<sub>10</sub>) and virtual eradication of bacteria (reduction ≥ 4 log<sub>10</sub>). MIC 600 μg/mL.</p>
Full article ">Figure 2 Cont.
<p>(<b>A</b>) Lethality curve of different concentrations of carvacrol against a 10<sup>8</sup> CFU/mL inoculum of <span class="html-italic">Salmonella</span> Typhimurium ATCC 14028. (<b>B</b>) Enlargement of the results obtained in the first hour of the test. The horizontal dotted lines represent the theoretical cut-off points to evaluate the efficacy of the antimicrobial (reduction with respect to the initial inoculum): bacteriostatic effect (reduction ≥ 2 log<sub>10</sub>), bactericidal (reduction ≥ 3 log<sub>10</sub>) and virtual eradication of bacteria (reduction ≥ 4 log<sub>10</sub>). MIC 600 μg/mL.</p>
Full article ">Figure 3
<p>PAE and PA-SME of different carvacrol concentrations for a standard-density inoculum (10<sup>6</sup> CFU/mL) of <span class="html-italic">S</span>. Typhimurium ATCC 14028. Pre: The time of beginning exposure to the carvacrol. Post: The time of discontinuing exposure to the carvacrol. MIC = 600 μg/mL; subMIC tested = 150 μg/mL.</p>
Full article ">Figure 4
<p>PAE and PA-SME of different carvacrol concentrations for a high-density inoculum (10<sup>8</sup> CFU/mL) of <span class="html-italic">S</span>. Typhimurium ATCC 14028. Pre: The time of beginning exposure to the carvacrol. Post: The time of discontinuing exposure to the carvacrol. MIC = 600 μg/mL; subMIC tested = 150 μg/mL.</p>
Full article ">
9 pages, 4149 KiB  
Communication
Synergistic Activity of Cefiderocol in Combination with Avibactam, Sulbactam or Tazobactam against Carbapenem-Resistant Gram-Negative Bacteria
by Russell E. Lewis, Marta Palombo, Erica Diani, Benedetta Secci, Davide Gibellini and Paolo Gaibani
Cells 2024, 13(16), 1315; https://doi.org/10.3390/cells13161315 - 6 Aug 2024
Cited by 1 | Viewed by 1304
Abstract
We investigated the activity of cefiderocol/β-lactamase inhibitor combinations against clinical strains with different susceptibility profiles to cefiderocol to explore the potentiality of antibiotic combinations as a strategy to contain the major public health problem of multidrug-resistant (MDR) pathogens. Specifically, we evaluated the synergistic [...] Read more.
We investigated the activity of cefiderocol/β-lactamase inhibitor combinations against clinical strains with different susceptibility profiles to cefiderocol to explore the potentiality of antibiotic combinations as a strategy to contain the major public health problem of multidrug-resistant (MDR) pathogens. Specifically, we evaluated the synergistic activity of cefiderocol with avibactam, sulbactam, or tazobactam on three of the most “Critical Priority” group of MDR bacteria (carbapenem-resistant Enterobacterales, Pseudomonas aeruginosa, and Acinetobacter baumannii). Clinical isolates were genomically characterized by Illumina iSeq 100. The synergy test was conducted with time-kill curve assays. Specifically, cefiderocol/avibactam, /sulbactam, or /tazobactam combinations were analyzed. Synergism was assigned if bacterial grow reduction reached 2 log10 CFU/mL. We reported the high antimicrobial activity of the cefiderocol/sulbactam combination against carbapenem-resistant Enterobacterales, P. aeruginosa, and A. baumannii; of the cefiderocol/avibactam combination against carbapenem-resistant Enterobacterales; and of the cefiderocol/tazobactam combination against carbapenem-resistant Enterobacterales and P. aeruginosa. Our results demonstrate that all β-lactamase inhibitors (BLIs) tested are able to enhance cefiderocol antimicrobial activity, also against cefiderocol-resistant isolates. The cefiderocol/sulbactam combination emerges as the most promising combination, proving to highly enhance cefiderocol activity in all the analyzed carbapenem-resistant Gram-negative isolates, whereas the Cefiderocol/tazobactam combination resulted in being active only against carbapenem-resistant Enterobacterales and P. aeruginosa, and cefiderocol/avibactam was only active against carbapenem-resistant Enterobacterales. Full article
(This article belongs to the Special Issue Mechanisms of Antimicrobial Treatment in Human Diseases)
Show Figures

Figure 1

Figure 1
<p>TKC obtained for CRE, CFD-susceptible (<b>A</b>–<b>C</b>), and CFD-resistant (<b>D</b>–<b>F</b>); for CR-Pa, CFD-susceptible (<b>G</b>–<b>I</b>), and CFD-resistant (<b>J</b>–<b>L</b>); and for CR-Ab, CFD-susceptible (<b>M</b>–<b>O</b>), and CFD-resistant (<b>P</b>–<b>R</b>) with CFD in combination with avibactam (<b>A</b>,<b>D</b>,<b>G</b>,<b>J</b>,<b>M</b>,<b>P</b>), sulbactam (<b>B</b>,<b>E</b>,<b>H</b>,<b>K</b>,<b>N</b>,<b>Q</b>), and tazobactam (<b>C</b>,<b>F</b>,<b>I</b>,<b>L</b>,<b>O</b>,<b>R</b>).</p>
Full article ">Figure 2
<p>The average (mean R) CFU/mL deviation from null response interaction model for tested cefiderocol (CFD)-β-lactamase inhibitor combinations at 24 h determined by time-kill curve analysis. Negative mean R values are indicative of average synergistic effects; positive values are indicative of average antagonistic effects.</p>
Full article ">
15 pages, 1062 KiB  
Review
New Delhi Metallo-Beta-Lactamase Inhibitors: A Systematic Scoping Review
by Lutfun Nahar, Hideharu Hagiya, Kazuyoshi Gotoh, Md Asaduzzaman and Fumio Otsuka
J. Clin. Med. 2024, 13(14), 4199; https://doi.org/10.3390/jcm13144199 - 18 Jul 2024
Cited by 1 | Viewed by 2096
Abstract
Background/Objectives: Among various carbapenemases, New Delhi metallo-beta-lactamases (NDMs) are recognized as the most powerful type capable of hydrolyzing all beta-lactam antibiotics, often conferring multi-drug resistance to the microorganism. The objective of this review is to synthesize current scientific data on NDM inhibitors [...] Read more.
Background/Objectives: Among various carbapenemases, New Delhi metallo-beta-lactamases (NDMs) are recognized as the most powerful type capable of hydrolyzing all beta-lactam antibiotics, often conferring multi-drug resistance to the microorganism. The objective of this review is to synthesize current scientific data on NDM inhibitors to facilitate the development of future therapeutics for challenging-to-treat pathogens. Methods: Following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) Extension for Scoping Reviews, we conducted a MEDLINE search for articles with relevant keywords from the beginning of 2009 to December 2022. We employed various generic terms to encompass all the literature ever published on potential NDM inhibitors. Results: Out of the 1760 articles identified through the database search, 91 met the eligibility criteria and were included in our analysis. The fractional inhibitory concentration index was assessed using the checkerboard assay for 47 compounds in 37 articles, which included 8 compounds already approved by the Food and Drug Administration (FDA) of the United States. Time-killing curve assays (14 studies, 25%), kinetic assays (15 studies, 40.5%), molecular investigations (25 studies, 67.6%), in vivo studies (14 studies, 37.8%), and toxicity assays (13 studies, 35.1%) were also conducted to strengthen the laboratory-level evidence of the potential inhibitors. None of them appeared to have been applied to human infections. Conclusions: Ongoing research efforts have identified several potential NDM inhibitors; however, there are currently no clinically applicable drugs. To address this, we must foster interdisciplinary and multifaceted collaborations by broadening our own horizons. Full article
(This article belongs to the Section Infectious Diseases)
Show Figures

Figure 1

Figure 1
<p>Flowchart of the study process.</p>
Full article ">Figure 2
<p>Annual numbers of eligible articles, by publication year.</p>
Full article ">
16 pages, 6829 KiB  
Article
Synergistic Bactericidal Effects of Quaternary Ammonium Compounds with Essential Oil Constituents
by Adrián Pedreira, Susana Fernandes, Manuel Simões, Míriam R. García and José Antonio Vázquez
Foods 2024, 13(12), 1831; https://doi.org/10.3390/foods13121831 - 11 Jun 2024
Cited by 2 | Viewed by 1936
Abstract
Antimicrobial tolerance is a significant concern in the food industry, as it poses risks to food safety and public health. To overcome this challenge, synergistic combinations of antimicrobials have emerged as a potential solution. In this study, the combinations of two essential oil [...] Read more.
Antimicrobial tolerance is a significant concern in the food industry, as it poses risks to food safety and public health. To overcome this challenge, synergistic combinations of antimicrobials have emerged as a potential solution. In this study, the combinations of two essential oil constituents (EOCs), namely carvacrol (CAR) and eugenol (EUG), with the quaternary ammonium compounds (QACs) benzalkonium chloride (BAC) and didecyldimethylammonium chloride (DDAC) were evaluated for their antimicrobial effects against Escherichia coli and Bacillus cereus, two common foodborne bacteria. The checkerboard assay was employed to determine the fractional inhibitory concentration index (FICI) and the fractional bactericidal concentration index (FBCI), indicating the presence of bactericidal, but not bacteriostatic, synergy in all QAC–EOC combinations. Bactericidal synergism was clearly supported by Bliss independence analysis. The bactericidal activity of the promising synergistic combinations was further validated by time–kill curves, achieving a >4-log10 reduction of initial bacterial load, which is significant compared to typical industry standards. The combinations containing DDAC showed the highest efficiency, resulting in the eradication of bacterial population in less than 2–4 h. These findings emphasize the importance of considering both bacteriostatic and bactericidal effects when evaluating antimicrobial combinations and the potential of EOC–QAC combinations for sanitization and disinfection in the food industry. Full article
Show Figures

Figure 1

Figure 1
<p>Response surface data analysis of the bactericidal effect of QAC/EOC combinations obtained using Bliss Independence model. Each graph was generated using the mean of three separate experiments, each consisting of three replicates.</p>
Full article ">Figure 2
<p>Time–kill curves show the inactivation dynamics of the selected QAC–EOC combinations and their components over <span class="html-italic">B. cereus</span>. Model output is depicted by lines, while experimental data is represented by markers. The dashed line represents the detection limit (2-log<sub>10</sub> CFUs/mL). Error bars depict the standard deviation of two independent experiments with replicates.</p>
Full article ">Figure 3
<p>Time–kill curves show the inactivation dynamics of the selected QAC–EOC combinations and their components over <span class="html-italic">E. coli</span>. Model output is depicted by lines, while experimental data is represented by markers. The dashed line represents the detection limit (2-log<sub>10</sub> CFUs/mL). Error bars depict the standard deviation of two independent experiments with replicates.</p>
Full article ">
11 pages, 1536 KiB  
Article
Antimicrobial and Antibiofilm Effects of Bithionol against Mycobacterium abscessus
by Dan Cao, Xin Yuan, Xiuzhi Jiang, Tiantian Wu, Yanghui Xiang, Zhongkang Ji, Jiaying Liu, Xu Dong, Kefan Bi, Tone Tønjum, Kaijin Xu and Ying Zhang
Antibiotics 2024, 13(6), 529; https://doi.org/10.3390/antibiotics13060529 - 5 Jun 2024
Viewed by 1710
Abstract
Mycobacterium abscessus (M. abscessus) is a multidrug-resistant nontuberculous mycobacterium (NTM) that is responsible for a wide spectrum of infections in humans. The lack of effective bactericidal drugs and the formation of biofilm make its clinical treatment very difficult. The FDA-approved drug [...] Read more.
Mycobacterium abscessus (M. abscessus) is a multidrug-resistant nontuberculous mycobacterium (NTM) that is responsible for a wide spectrum of infections in humans. The lack of effective bactericidal drugs and the formation of biofilm make its clinical treatment very difficult. The FDA-approved drug library containing 3048 marketed and pharmacopeial drugs or compounds was screened at 20 μM against M. abscessus type strain 19977 in 7H9 medium, and 62 hits with potential antimicrobial activity against M. abscessus were identified. Among them, bithionol, a clinically approved antiparasitic agent, showed excellent antibacterial activity and inhibited the growth of three different subtypes of M. abscessus from 0.625 μM to 2.5 μM. We confirmed the bactericidal activity of bithionol by the MBC/MIC ratio being ≤4 and the time–kill curve study and also electron microscopy study. Interestingly, it was found that at 128 μg/mL, bithionol could completely eliminate biofilms after 48h, demonstrating an outstanding antibiofilm capability compared to commonly used antibiotics. Additionally, bithionol could eliminate 99.9% of biofilm bacteria at 64 μg/mL, 99% at 32 μg/mL, and 90% at 16 μg/mL. Therefore, bithionol may be a potential candidate for the treatment of M. abscessus infections due to its significant antimicrobial and antibiofilm activities. Full article
Show Figures

Figure 1

Figure 1
<p>Time–kill curves of (<b>A</b>) bithionol and (<b>B</b>) clarithromycin against <span class="html-italic">M. abscessus</span> 19977 in 7H9 medium supplemented with 1% glucose at different drug concentrations. Drug concentrations are indicated by different symbols.</p>
Full article ">Figure 2
<p>Determination of antibiofilm activity of bithionol. <span class="html-italic">M. abscessus</span> 19977 was cultured in Sauton’s medium in a 24-well plate at 37 °C for 6 days and biofilms formed on the liquid–air interface. Clarithromycin, amikacin, moxifloxacin, and bithionol at final concentrations of 8, 16, 32, 64, and 128 μg/mL were added to wells and incubated at 37 °C for 48h. Then, the biofilms were collected and CFU counts were determined.</p>
Full article ">Figure 3
<p>SEM images of bithionol treatment of <span class="html-italic">M. abscessus</span>. (<b>A</b>) <span class="html-italic">M. abscessus</span> control group treated with PBS; (<b>B</b>) <span class="html-italic">M. abscessus</span> bacteria treated with bithionol at 2 μg/mL for 24 h. The bars of the left panel indicate 5 μm, while the bars of the right panel indicate 1 μm.</p>
Full article ">
13 pages, 2740 KiB  
Article
Susceptibility of Fall Armyworm Field Populations to Vip3Aa/Cry Bt Maize in a Tropical Agricultural Region
by Alisson Franco T. Silva, Luciana B. Silva, José B. Malaquias, Angélica S. Salustino, Domingos Francisco Correia Neto, Daniel M. Pacheco, Daniel B. Fragoso and Eliseu J. G. Pereira
Agronomy 2024, 14(3), 451; https://doi.org/10.3390/agronomy14030451 - 24 Feb 2024
Viewed by 1987
Abstract
Fall armyworm (FAW, Spodoptera frugiperda) is a polyphagous and migratory lepidopteran pest insect in field crops and is notoriously invasive worldwide. In large portions of the Americas, its populations are managed using transgenic maize or cotton varieties producing insecticidal proteins from Bacillus [...] Read more.
Fall armyworm (FAW, Spodoptera frugiperda) is a polyphagous and migratory lepidopteran pest insect in field crops and is notoriously invasive worldwide. In large portions of the Americas, its populations are managed using transgenic maize or cotton varieties producing insecticidal proteins from Bacillus thuringiensis (Bt), primarily Vip3Aa pyramided with Cry Bt proteins. We determined the susceptibility of FAW field populations from locations pressured with such maize hybrids for over five years. We used time–mortality bioassays with F1 third-instar larvae of six geographically distinct populations collected in maize fields of a tropical agricultural region encompassing four Brazilian states. We maintained the neonate progeny from the field populations on an artificial diet until the third instar, and then determined their survival curves on the foliage of three Vip3Aa/Cry-producing Bt maize hybrids. Death of the mid-size, third-instar FAWs occurred relatively rapidly, with larval mortality rates reaching 98–100% in less than five days regardless of Bt maize hybrid. However, median survival time (ST50) for the larvae differed among the populations, with the lowest and highest ST50 values occurring for PI-Cr (42 h, 1.75 d) and PI-Ur populations (66–90 h, 2.75–3.75 h), respectively. Therefore, the F1 third-instar larvae of FAW populations were largely susceptible to Vip3Aa/Cry-producing maize foliage, and the most contrasting susceptibility occurred in the insects from Piauí state, Brazil. These results indicate that progeny of FAWs from areas highly pressured with Vip3Aa/Cry Bt maize hybrids are killed on maize foliage producing Vip3Aa and Cry Bt proteins despite field reports of increased leaf damage by the larvae in some locations. This research informs decision making for Bt-crop resistance management by producers, technicians, and researchers in local, regional, and world agriculture. Full article
(This article belongs to the Section Pest and Disease Management)
Show Figures

Figure 1

Figure 1
<p>Sampling sites of the field populations of fall armyworm (<span class="html-italic">Spodoptera frugiperda</span>). Shown is a graphical representation of the ‘Matopiba’ region, formed by the Brazilian states of Maranhão (MA), Tocatins (TO), Piauí (PI), and Bahia (BA), where the insects were collected.</p>
Full article ">Figure 2
<p>Larval survival curves for fall armyworm populations (<span class="html-italic">Spodoptera frugiperda</span>) feeding on maize leaf tissues producing Vip3Aa/Cry Bt proteins. The third-instar larvae exposed are progeny from individuals collected in maize fields of a tropical agricultural frontier region in Brazil. The population codes are as follows: (<b>A</b>) MA-Bs, (<b>B</b>) TO-PN, (<b>C</b>) PI-BG, (<b>D</b>) PI-Cs, (<b>E</b>) PI-Ur, and (<b>F</b>) BA-LE. <span class="html-fig-inline" id="agronomy-14-00451-i001"><img alt="Agronomy 14 00451 i001" src="/agronomy/agronomy-14-00451/article_deploy/html/images/agronomy-14-00451-i001.png"/></span> Non-Bt; <span class="html-fig-inline" id="agronomy-14-00451-i002"><img alt="Agronomy 14 00451 i002" src="/agronomy/agronomy-14-00451/article_deploy/html/images/agronomy-14-00451-i002.png"/></span> Cry1F + Cry1Ab + Vip3Aa; <span class="html-fig-inline" id="agronomy-14-00451-i003"><img alt="Agronomy 14 00451 i003" src="/agronomy/agronomy-14-00451/article_deploy/html/images/agronomy-14-00451-i003.png"/></span> Cry1A.105 + Cry2Ab + Vip3Aa; <span class="html-fig-inline" id="agronomy-14-00451-i004"><img alt="Agronomy 14 00451 i004" src="/agronomy/agronomy-14-00451/article_deploy/html/images/agronomy-14-00451-i004.png"/></span> Cry1F + Cry1A.105 + Cry2Ab + Vip3Aa.</p>
Full article ">Figure 3
<p>Mortality dynamics of third-instar fall armyworms (<span class="html-italic">Spodoptera frugiperda</span>) as affected by Vip3Aa/Cry-producing Bt maize hybrids. The larvae derived from field collections in a region of a tropical agricultural frontier in Brazil. (<b>A</b>) Mortality schedule. (<b>B</b>) Mean survival time. Columns with the same line segments are not significantly different (<span class="html-italic">p</span> &gt; 0.05, Tukey’s HSD adjustment).</p>
Full article ">Figure 4
<p>Comparative time–mortality responses of third-instar fall armyworms (<span class="html-italic">Spodoptera frugiperda</span>) of six populations collected in a tropical agricultural frontier region. The larvae were assayed using foliage maize hybrids representing following lepidopteran-active Bt traits (maize hybrids): (<b>A</b>) non-Bt (30F53RR), (<b>B</b>) Cry1A + Cry1F + Vip3Aa (30F53VHYR), (<b>C</b>) Cry1A.105 + Cry2Ab + Vip3A (DKB390PRO4), and (<b>D</b>) Cry1F + Cry1A.105 + Cry2Ab + Vip3A (P3551PWU).</p>
Full article ">Figure 5
<p>Overall Vip3Aa/Cry susceptibility of the fall armyworm (<span class="html-italic">Spodoptera frugiperda</span>) populations. Third-instar larvae were assayed with fresh leaf tissues of three Bt maize hybrids producing the protein. (A) Mortality schedule across the three Bt maize hybrids. (<b>B</b>) Median survival time values as a summary of the results. Error bars are 95% confidence limits. Columns with the same letter do not differ if confidence intervals do not overlap their origins (<span class="html-italic">p</span> &gt; 0.05).</p>
Full article ">
16 pages, 2317 KiB  
Article
Fighting Microbial Infections from Escherichia coli O157:H7: The Combined Use of Three Essential Oils of the Cymbopogon Genus and a Derivative of Esculentin-1a Peptide
by Raffaella Scotti, Bruno Casciaro, Annarita Stringaro, Filippo Maggi, Marisa Colone and Roberta Gabbianelli
Antibiotics 2024, 13(1), 86; https://doi.org/10.3390/antibiotics13010086 - 16 Jan 2024
Cited by 3 | Viewed by 1993
Abstract
The absence of effective therapy against Escherichia coli O157:H7 infections has led to the need to develop new antimicrobial agents. As the use of synergistic combinations of natural antimicrobial compounds is growing as a new weapon in the fight against multidrug-resistant bacteria, here, [...] Read more.
The absence of effective therapy against Escherichia coli O157:H7 infections has led to the need to develop new antimicrobial agents. As the use of synergistic combinations of natural antimicrobial compounds is growing as a new weapon in the fight against multidrug-resistant bacteria, here, we have tested new synergistic combinations of natural agents. Notably, we investigated a possible synergistic effect of combinations of essential oils and natural peptides to counteract the formation of biofilm. We chose three essential oils (i.e., Cymbopogon citratus, C. flexuosus and C. martinii) and one peptide already studied in our previous works. We determined the fractional inhibitory concentration (FIC) by analyzing the combination of the peptide derived from esculentin-1a, Esc(1–21), with the three essential oils. We also studied the effects of combinations by time–kill curves, scanning electron microscopy on biofilm and Sytox Green on cell membrane permeability. Finally, we analyzed the expression of different genes implicated in motility, biofilm formation and stress responses. The results showed a different pattern of gene expression in bacteria treated with the mixtures compared to those treated with the peptide or the single C. citratus essential oil. In conclusion, we demonstrated that the three essential oils used in combination with the peptide showed synergy against the E. coli O157:H7, proving attractive as an alternative strategy against E. coli pathogen infections. Full article
Show Figures

Figure 1

Figure 1
<p>Time–kill curves of <span class="html-italic">C. citratus, C. flexuosus, C. martinii</span> and Esc(1–21) alone or in combination against EDL933 (<b>A</b>) and K12 (<b>B</b>) strains. Each component alone and in combination was used at ¼ of the respective MICs. The strains without any treatment were considered to be the control (CTR). The experiments were performed in triplicate. Data were expressed as means ± SDs.</p>
Full article ">Figure 2
<p>Scanning microscopy images of biofilm formed by <span class="html-italic">E. coli</span> strains in the absence or presence of EO/Esc(1–21) mixtures, used at a concentration of 1/4 FIC for 24 h. In detail, for the <span class="html-italic">C. flexuosus/</span>Esc(1–21) combination, we used 0.00156%/0.125 µM and 0.00312%/0.0156 µM for EDL933 and K12 strains, respectively; <span class="html-italic">C. citratus/</span>Esc(1–21) combinations of 0.0125%/0.0078 µM and 0.00625%/0.0625 µM were used for EDL933 and K12 strains, respectively; and <span class="html-italic">C. martinii</span>/Esc(1–21) combinations of 0.0125%/0.0039 µM and 0.0125%/0.0078 µM were used for EDL933 and K12 strains, respectively. (<b>A</b>,<b>E</b>) referred to the untreated EDL933 and K12 strains, respectively. The EOs used in combination with the peptide were <span class="html-italic">C. flexuosus</span> (<b>B</b>,<b>F</b>), <span class="html-italic">C. citratus</span> (<b>C</b>,<b>G</b>) and <span class="html-italic">C. martinii</span> (<b>D</b>,<b>H</b>).</p>
Full article ">Figure 3
<p>Effect of the presence of Esc(1–21), oils (<b>A</b>) and their combinations (<b>B</b>) on the membrane permeability of the EDL933 strain. The Sytox Green dye was used, and changes in fluorescence were monitored. Time 0 indicates the addition of the compounds. We performed three independent experiments and reported data from a single representative experiment.</p>
Full article ">Figure 4
<p>RT-PCR analysis of expression changes in genes related to flagellar system regulation, biofilm formation (<b>A</b>) and oxidative and osmotic stresses (<b>B</b>). Relative gene expressions (RQ) represent transcriptional levels after the exposure of <span class="html-italic">E. coli</span> EDL933 to singular components or mixtures versus the untreated control (CTR). The reference gene 16<span class="html-italic">s</span> rRNA was used to normalize the gene transcription level. Data are expressed as means ± SDs of three independent experiments performed in triplicate. * <span class="html-italic">p</span> ≤ 0.05.</p>
Full article ">
20 pages, 4615 KiB  
Article
Synergistic Activity and Mechanism of Sanguinarine with Polymyxin B against Gram-Negative Bacterial Infections
by Luyao Qiao, Yu Zhang, Ying Chen, Xiangyin Chi, Jinwen Ding, Hongjuan Zhang, Yanxing Han, Bo Zhang, Jiandong Jiang and Yuan Lin
Pharmaceutics 2024, 16(1), 70; https://doi.org/10.3390/pharmaceutics16010070 - 3 Jan 2024
Cited by 1 | Viewed by 2083
Abstract
Compounds that potentiate the activity of clinically available antibiotics provide a complementary solution, except for developing novel antibiotics for the rapid emergence of multidrug-resistant Gram-negative bacteria (GNB). We sought to identify compounds potentiating polymyxin B (PMB), a traditional drug that has been revived [...] Read more.
Compounds that potentiate the activity of clinically available antibiotics provide a complementary solution, except for developing novel antibiotics for the rapid emergence of multidrug-resistant Gram-negative bacteria (GNB). We sought to identify compounds potentiating polymyxin B (PMB), a traditional drug that has been revived as the last line for treating life-threatening GNB infections, thus reducing its nephrotoxicity and heterogeneous resistance in clinical use. In this study, we found a natural product, sanguinarine (SA), which potentiated the efficacy of PMB against GNB infections. The synergistic effect of SA with PMB was evaluated using a checkerboard assay and time–kill curves in vivo and the murine peritonitis model induced by Escherichia coli in female CD-1 mice in vivo. SA assisted PMB in accelerating the reduction in bacterial loads both in vitro and in vivo, improving the inflammatory responses and survival rate of infected animals. The subsequent detection of the intracellular ATP levels, membrane potential, and membrane integrity indicated that SA enhanced the bacterial-membrane-breaking capacity of PMB. A metabolomic analysis showed that the inhibition of energy metabolism, interference with nucleic acid biosynthesis, and the blocking of L-Ara4N-related PMB resistance may also contribute to the synergistic effect. This study is the first to reveal the synergistic activity and mechanism of SA with PMB, which highlights further insights into anti-GNB drug development. Full article
(This article belongs to the Special Issue Novel Drugs, Targets and Therapies Against Infectious Diseases)
Show Figures

Figure 1

Figure 1
<p>Identification of compounds that potentiate the antibacterial activity of PMB. (<b>a</b>) Left: diagrammatic drawing of the initial screen, which was conducted at 1/2 × MIC PMB in combination with 10 μM compounds against <span class="html-italic">E. coli</span> ATCC 25922; Right: a dot plot diagram of results that represents the screening data for the compounds, with the red dashed line delineating the cut-off for compounds with OD<sub>600</sub> &lt; 0.1. The four red dots represent the positive compounds in the initial screen. (<b>b</b>) Left: diagrammatic drawing of the secondary screen, which was conducted at 1/2 × MIC PMB in combination with the initial positive compounds at different concentrations starting from 10 μM in 2-fold dilutions; Right: OD<sub>600</sub> of different combined treatments in the secondary screen. (<b>c</b>) Chemical structure of sanguinarine.</p>
Full article ">Figure 2
<p>In vitro antibacterial activity of PMB-SA combinations against GNB strains. (<b>a</b>) Checkerboard assays of PMB-SA combinations. OD<sub>600</sub> values were measured using a plate reader and transformed into a color gradient indicated by a scale: dark blue represents growth, while white represents no growth. The red boxes indicate combinations with the highest synergistic activity. (<b>b</b>) Time–kill curves of GNBs treated with PMB, SA, and PMB-SA combination with concentrations in FICI. The detection limit is indicated by a dotted line (10 CFU/mL).</p>
Full article ">Figure 3
<p>In vivo antibacterial activity of PMB-SA combination in murine peritonitis model. (<b>a</b>) Scheme of the experimental protocol. <span class="html-italic">E. coli</span> ATCC 25922 was intraperitoneally injected, and 0.5 mg/kg PMB and 10 mg/kg SA were used for treatment. (<b>b</b>) Animal survival rates within 7 days in each group (n = 18). (<b>c</b>) Pathological sections with H&amp;E staining of livers, kidneys, and spleens in each group. Scale bars are 50 μm for livers/kidneys and 100 μm for spleens. (<b>d</b>) Bacterial loads were determined in blood, peritoneal lavage fluids, livers, kidneys, and spleens in CFU per ml and mg, respectively (n = 5). The detection limit is indicated by a dotted line (10 CFU/mL). (<b>e</b>) Assays of proinflammatory cytokines IL-6, IL-1<span class="html-italic">β</span>, and TNF-<span class="html-italic">α</span> in plasma according to ELISA (n = 5). All data are expressed as mean ± SD (error bars). * <span class="html-italic">p</span> &lt; 0.05, ** <span class="html-italic">p</span> &lt; 0.01, *** <span class="html-italic">p</span> &lt; 0.001, **** <span class="html-italic">p</span> &lt; 0.0001. Welch’s one-way ANOVA with Dunnett’s T3 multiple-comparison test was used. The survival rate was analyzed using a log-rank (Mantel–Cox) test.</p>
Full article ">Figure 4
<p>The synergy mechanism of SA with PMB. (<b>a</b>) Determination of intracellular ATP using a luminescence-based assay. (<b>b</b>) Fluctuation of bacterial membrane potential with the DiOC<sub>2</sub> fluorescence-based method. (<b>c</b>) Changes in bacterial membrane permeability. The Ctrl-v group represents the viable control with untreated bacteria. The Ctrl-d group represents the dead control with bacteria killed by heating. MFI: median fluorescence intensity. The MFI ratio is defined as the MFI of each group over the MFI of the Ctrl-v group. (<b>d</b>) Morphological observations by scanning electron microscopy (SEM) and transmission electron microscopy (TEM). PMB (1/16 × MIC) and SA (1/4 × MIC) were used. Red arrow: tubular appendages; white arrow: damaged bacterial membrane; blue arrow: mesosomes; green arrow: inhomogeneous cytoplasm with abnormally increasing electron density; yellow arrow: loose cytoplasm; purple arrow: incomplete cell envelope structure. Scale bars were 1 μm and 500 nm, as indicated for SEM and TEM, respectively. All data are based on values obtained from three replicates (n = 3) and are expressed as mean ± SD (error bars). At least three technical replicates were run with each biological replicate. * <span class="html-italic">p</span> &lt; 0.05, ** <span class="html-italic">p</span> &lt; 0.01, **** <span class="html-italic">p</span> &lt; 0.0001. Welch’s one-way ANOVA with Dunnett’s T3 multiple-comparison test was used.</p>
Full article ">Figure 5
<p>Metabolomic analysis associated with membrane perturbations of <span class="html-italic">E. coli</span> treated with PMB and SA. (<b>a</b>) Significantly perturbed fatty acids and glycerol phospholipids in <span class="html-italic">E. coli</span> ATCC 25922 treated with the compounds are shown in the bar graph (<span class="html-italic">p</span> ≤ 0.05). FAs: fatty acids; GLPs: glycerol phospholipids; FA<sub>a</sub>: Blumenol-CO-[rhamnosyl-(1-&gt;6)-glucoside]; FA<sub>b</sub>: 3-O-(<span class="html-italic">α</span>-L-arabinopyranosyl-(1-&gt;6)-<span class="html-italic">β</span>-D-glucopyranosyl) butyl 3R-hydroxybutanoate; FA<sub>c</sub>: Butyl (S)-3-hydroxybutyrate [arabinosyl-(1-&gt;6)-glucoside]. (<b>b</b>) Integrated pathway map of metabolites of <span class="html-italic">E. coli</span> ATCC 25922 significantly impacted by PMB, SA, and their combination in interrelated pathways: arginine pathway, glycolysis pathway, amino sugar/nucleotide sugar metabolism, and pentose phosphate pathway. Bar charts for the significantly impacted metabolites of these pathways following treatment with PMB (2 × MIC), SA (2 × MIC), or their combination for 1 h (<span class="html-italic">p</span> &lt; 0.05). (<b>c</b>) Integrated pathway map of metabolites in <span class="html-italic">E. coli</span> ATCC 25922 significantly impacted by PMB, SA, and their combination in pathways of L-Ara4N-related PMB resistance. Bar charts for the significantly impacted metabolites of these pathways following treatment with PMB (2 × MIC), SA (2 × MIC), or their combination for 1 h (<span class="html-italic">p</span> &lt; 0.05). Metabolites in red boxes were significantly increased after PMB-SA combination treatment compared to PMB alone, while in blue boxes were significantly decreased and in black boxes were no changes. Dotted arrows indicated indirect relationships between metabolites. * <span class="html-italic">p</span> &lt; 0.05, ** <span class="html-italic">p</span> &lt; 0.01, *** <span class="html-italic">p</span> &lt; 0.001, **** <span class="html-italic">p</span> &lt; 0.0001. All data were obtained from six replicates (n = 6) and are expressed as mean ± SD (error bars). Student’s <span class="html-italic">t</span>-test was used to analyze the results.</p>
Full article ">
11 pages, 2411 KiB  
Article
A Pharmacodynamic Study of Aminoglycosides against Pathogenic E. coli through Monte Carlo Simulation
by Eon-Bee Lee and Kyubae Lee
Pharmaceuticals 2024, 17(1), 27; https://doi.org/10.3390/ph17010027 - 24 Dec 2023
Cited by 1 | Viewed by 2247
Abstract
This research focuses on combating the increasing problem of antimicrobial resistance, especially in Escherichia coli (E. coli), by assessing the efficacy of aminoglycosides. The study specifically addresses the challenge of developing new therapeutic approaches by integrating experimental data with mathematical modeling [...] Read more.
This research focuses on combating the increasing problem of antimicrobial resistance, especially in Escherichia coli (E. coli), by assessing the efficacy of aminoglycosides. The study specifically addresses the challenge of developing new therapeutic approaches by integrating experimental data with mathematical modeling to better understand the action of aminoglycosides. It involves testing various antibiotics like streptomycin (SMN), kanamycin (KMN), gentamicin (GMN), tobramycin (TMN), and amikacin (AKN) against the O157:H7 strain of E. coli. The study employs a pharmacodynamics (PD) model to analyze how different antibiotic concentrations affect bacterial growth, utilizing minimum inhibitory concentration (MIC) to gauge the effective bactericidal levels of the antibiotics. The study’s approach involved transforming bacterial growth rates, as obtained from time–kill curve data, into logarithmic values. A model was then developed to correlate these log-transformed values with their respective responses. To generate additional data points, each value was systematically increased by an increment of 0.1. To simulate real-world variability and randomness in the data, a Gaussian scatter model, characterized by parameters like κ and EC50, was employed. The mathematical modeling was pivotal in uncovering the bactericidal properties of these antibiotics, indicating different PD MIC (zMIC) values for each (SMN: 1.22; KMN: 0.89; GMN: 0.21; TMN: 0.32; AKN: 0.13), which aligned with MIC values obtained through microdilution methods. This innovative blend of experimental and mathematical approaches in the study marks a significant advancement in formulating strategies to combat the growing threat of antimicrobial-resistant E. coli, offering a novel pathway to understand and tackle antimicrobial resistance more effectively. Full article
Show Figures

Figure 1

Figure 1
<p>Optical density at 600 nm of 5 aminoglycoside antibiotics with concentration variations between 0.03125 to 64 μg/mL. Streptomycin, SMN; kanamycin, KMN; gentamicin, GMN; tobramycin, TMN; amikacin, AKN.</p>
Full article ">Figure 2
<p>Time–kill curves and area under the curve (AUC) of viable cells against <span class="html-italic">E. coli</span> ATCC 43888. Bacterial count measurements of various antibiotics (SMN (<b>A</b>), KMN (<b>B</b>), GMN (<b>C</b>), TMN (<b>D</b>), AKN (<b>E</b>)) with various concentration (MIC, 2MIC and 4MIC) against <span class="html-italic">E. coli</span> for 24 h. (<b>F</b>) Comparative visualization of antibiotic effectiveness using AUC of viable cells. Color gradients in heat map symbolize the range of activity. Streptomycin, SMN; kanamycin, KMN; gentamicin, GMN; tobramycin, TMN; amikacin, AKN.</p>
Full article ">Figure 3
<p>Fitting the pharmacodynamic model to the time–kill curves. Streptomycin, SMN; kanamycin, KMN; gentamicin, GMN; tobramycin, TMN; amikacin, AKN.</p>
Full article ">Figure 4
<p>Gaussian scatter model via pharmacodynamic functions for five different antimicrobials. Streptomycin, SMN; kanamycin, KMN; gentamicin, GMN; tobramycin, TMN; amikacin, AKN.</p>
Full article ">Figure 5
<p>Simulated EC<sub>50</sub> and Hill coefficient by Monte Carlo method.</p>
Full article ">Figure 6
<p>Pharmacodynamic model of relationship between antibiotic concentration and bacterial growth. Ψ represents the net growth rate of the bacteria. ψ <sub>max</sub> and ψ <sub>min</sub> are maximal bacterial growth rate and minimal bacterial growth rate. κ defined as Hill coefficient is the steepness of the curve.</p>
Full article ">
Back to TopTop